RxDoctor Payments Data

Scott Woods, MD

Family Medicine · Cincinnati, OHNPI 1093706061

Payments from drug & device makers

$5,959in general payments, 2019–2025

Across 125 payments — averaging $47.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • AstraZeneca$631
  • Abbott$419
  • AbbVie$413
  • Bayer$342
  • GSK$324
  • plus $3K from 23 others

What the payments were for

  • Consulting fees$62510%
  • Food & beverage$5,33089%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,959 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$3,937
Medicare patients
29
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$47,330
JardianceEmpagliflozin30$39,954
EliquisApixaban17$28,319
OzempicSemaglutide13$16,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,371
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl48$7,820
Breo ElliptaFluticasone/Vilanterol11$4,458
SymbicortBudesonide/Formoterol Fumarate12$3,145
Albuterol Sulfate HfaAlbuterol Sulfate107$3,130
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen37$1,163
Atorvastatin Calcium141$959
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$959
Gabapentin87$905
Diclofenac Sodium20$721
Fluticasone Propionate41$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$94$47,33020 claims
Boehringer IngelheimJardiance$1,075$39,95430 claims
PfizerEliquis$140$28,31917 claims
Novo NordiskOzempic$158$16,05013 claims
GSKTrelegy Ellipta, Breo Ellipta$324$14,82924 claims
AstraZenecaSymbicort$631$3,14512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →